Suchergebnisse - "Sun, Sanyuan"

PubPharm (48)

1

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients : a single-arm, multicenter phase II study (INTELLECT)

enthalten in: BMC medicine | 2023

von Shi, Y. | Chen, J. | Zhang, H. | +30

2

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

enthalten in: BMC medicine | 2023

von Shi, Y. | Chen, J. | Zhang, H. | +30

3

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

enthalten in: BMC medicine | 2023

von Shi, Y. | Chen, J. | Zhang, H. | +30

4

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer : an open-label, randomized controlled phase 3 trial (ORIENT-3)

enthalten in: Cancer communications (London, England) | 2022

von Shi, Y. | Wu, L. | Yu, X. | +43

5

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

enthalten in: JTO clinical and research reports | 2022

von Lu, S. | Fang, J. | Li, X. | +21

6

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations : a post hoc analysis of a pivotal phase 2 study

enthalten in: Therapeutic advances in medical oncology | 2022

von Yu, Y. | Ren, Y. | Fang, J. | +27

7

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer : an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

enthalten in: Cancer Communications | 2022

von Shi, Y. | Wu, L. | Yu, X. | +43

8

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer : a phase 3 randomized, double-blind study

enthalten in: EClinicalMedicine | 2021

von Wan, R. | Dong, X. | Chen, Q. | +52

9

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations : a multicentre, single-arm, open-label, phase 2 study

enthalten in: The Lancet. Respiratory medicine | 2021

von Lu, S. | Fang, J. | Li, X. | +21

10

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma : The ESCORT-1st Randomized Clinical Trial

enthalten in: JAMA | 2021

von Luo, H. | Lu, J. | Bai, Y. | +62

CommentIn: JAMA Oncol. 2021 Nov 1;7(11):1613-1614. - PMID 34519775

1
2
3
4
5
Nächster »
[5]